Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)
Primary Purpose
Depression
Status
Terminated
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Magnetic stimulator
Sponsored by
About this trial
This is an interventional treatment trial for Depression focused on measuring Resistant depression, Transcranial Magnetic Stimulation,, Neuroimaging
Eligibility Criteria
Inclusion Criteria: Major depression (according to DSM-IV)resistant to at least two medical antidepressant treatment of different pharmacological action, prescribed for at least one month each at an effective dosage, without therapeutical result. Hospitalisation in the service of an investigator Informed consent signed Exclusion Criteria: Presence of metallic parts inside the body (pace-maker, vascular clip, cardiac valve, prothesis...) Severe somatic or central nervous system disease Familial history of comitiality Pregnancy
Sites / Locations
- Albert Chenevier Hospital, Department of psychiatry
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
A
Arm Description
Outcomes
Primary Outcome Measures
The primary outcome will be measured at 2 weeks, using depression scales scores : Hamilton depression rating scale, and Montgomery and Asberg Depression Rating Scale
Secondary Outcome Measures
Depressive psychomotor retardation will be assessed at 2 weeks
All depression measures will be assessed at 4 weeks, 2 weeks after the end of the trial to evaluate the lasting effects.
Full Information
NCT ID
NCT00190216
First Posted
September 13, 2005
Last Updated
November 6, 2007
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, International Atomic Energy Agency
1. Study Identification
Unique Protocol Identification Number
NCT00190216
Brief Title
Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)
Official Title
Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression
Study Type
Interventional
2. Study Status
Record Verification Date
July 2005
Overall Recruitment Status
Terminated
Why Stopped
terminated
Study Start Date
December 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, International Atomic Energy Agency
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The hypothesis of this study was that transcranial magnetic stimulation (TMS) focused on hyperfunctional cerebral areas should be more effective in treating depressive symptoms than stimulations not taking into account the functional specificity of the patient. The goal was to compare the effects of "guided" TMS, using neuroimaging to guide TMS on dysfunctional cortical regions individually detected by neuroimaging, with "standard TMS", as used in most studies, over the left prefrontal cortex, and with sham TMS, in patients with resistant depression.
Detailed Description
The objectives of the study were :
To localize the site of lowest frontal activity in each patient with resistant depression, using PET to measure regional cerebral metabolic rates for glucose (rCMRGlu).
To demonstrate that high-frequency TMS (10Hz) guided on that site is more effective than standard or sham TMS, in resistant depressed patients, using a doubled blind controlled procedure.
To assess the effects of TMS on regional cerebral metabolism using rCMRGlu PET after 10 sessions of TMS treatments.
Depressed patients meeting DSM-IV criteria for Major Depressive Disorder, aged between 18 and 55, have been included. They met criteria for depression resistant to antidepressant drugs They were randomised in 3 groups: guided prefrontal TMS, standard left prefrontal and sham left prefrontal TMS.
rTMS was administered daily on working days, for two weeks. Ten stimuli per second (10Hz) were applied in 20 courses so that patients received 1600 stimuli per day. Guided TMS was on a prefrontal target corresponding to the highest statistically significant hyperfunctional cluster determined with rCMRGlu PET. Standard stimulation was left pre-frontal, 5 cm anterior to the optimal stimulation point of the abductor pollices brevis. Stimulation strength was chosen at 90% relative to motor threshold. Sham rTMS used a procedure identical to the real standard treatment, but using a sham coil.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
Keywords
Resistant depression, Transcranial Magnetic Stimulation,, Neuroimaging
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigator
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Magnetic stimulator
Primary Outcome Measure Information:
Title
The primary outcome will be measured at 2 weeks, using depression scales scores : Hamilton depression rating scale, and Montgomery and Asberg Depression Rating Scale
Time Frame
at 2 weeks
Secondary Outcome Measure Information:
Title
Depressive psychomotor retardation will be assessed at 2 weeks
Time Frame
at 2 weeks
Title
All depression measures will be assessed at 4 weeks, 2 weeks after the end of the trial to evaluate the lasting effects.
Time Frame
at 4 weeks, 2 weeks after the end of the trial
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Major depression (according to DSM-IV)resistant to at least two medical antidepressant treatment of different pharmacological action, prescribed for at least one month each at an effective dosage, without therapeutical result.
Hospitalisation in the service of an investigator
Informed consent signed
Exclusion Criteria:
Presence of metallic parts inside the body (pace-maker, vascular clip, cardiac valve, prothesis...)
Severe somatic or central nervous system disease
Familial history of comitiality
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Laure PAILLERE MARTINOT, MD; PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Albert Chenevier Hospital, Department of psychiatry
City
Creteil
ZIP/Postal Code
94000
Country
France
12. IPD Sharing Statement
Learn more about this trial
Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)
We'll reach out to this number within 24 hrs